On Friday, Viracta Therapeutics Inc (NASDAQ: VIRX) opened lower -4.37% from the last session, before settling in for the closing price of $0.16. Price fluctuations for VIRX have ranged from $0.15 to $1.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 134.94% over the past five years. Company’s average yearly earnings per share was noted 31.57% at the time writing. With a float of $27.94 million, this company’s outstanding shares have now reached $39.09 million.
Let’s look at the performance matrix of the company that is accounted for 40 employees. In terms of profitability, gross margin is 55.42%, operating margin of -6397.02%, and the pretax margin is -5865.72%.
Viracta Therapeutics Inc (VIRX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Viracta Therapeutics Inc is 29.69%, while institutional ownership is 13.08%. The most recent insider transaction that took place on Feb 27 ’24, was worth 2,493. In this transaction CFO and COO of this company sold 3,405 shares at a rate of $0.73, taking the stock ownership to the 102,306 shares. Before that another transaction happened on Nov 30 ’23, when Company’s President and CEO bought 52,094 for $0.49, making the entire transaction worth $25,734. This insider now owns 52,094 shares in total.
Viracta Therapeutics Inc (VIRX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.35 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.31) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.57% per share during the next fiscal year.
Viracta Therapeutics Inc (NASDAQ: VIRX) Trading Performance Indicators
Check out the current performance indicators for Viracta Therapeutics Inc (VIRX). In the past quarter, the stock posted a quick ratio of 0.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Viracta Therapeutics Inc (VIRX)
Viracta Therapeutics Inc (NASDAQ: VIRX) saw its 5-day average volume 0.68 million, a positive change from its year-to-date volume of 0.49 million. As of the previous 9 days, the stock’s Stochastic %D was 16.47%. Additionally, its Average True Range was 0.02.
During the past 100 days, Viracta Therapeutics Inc’s (VIRX) raw stochastic average was set at 4.16%, which indicates a significant decrease from 20.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.93% in the past 14 days, which was lower than the 78.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2185, while its 200-day Moving Average is $0.5637. Nevertheless, the first resistance level for the watch stands at $0.1621 in the near term. At $0.1732, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.1885. If the price goes on to break the first support level at $0.1357, it is likely to go to the next support level at $0.1204. Assuming the price breaks the second support level, the third support level stands at $0.1093.
Viracta Therapeutics Inc (NASDAQ: VIRX) Key Stats
There are currently 39,744K shares outstanding in the company with a market cap of 5.74 million. Presently, the company’s annual sales total 0 K according to its annual income of -51,060 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -9,830 K.
